Aminex Therapeutics key facts
as of Oct 2026- Operator of a drug development company intended to focus on advancing novel immunotherapy for cancer treatment and cure.
- Aminex Therapeutics is valued at approximately $105.1M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $47.6M across 6 recorded rounds; the latest was Early Stage VC ($15.1M) in Oct 2022.
- Notable investors include United States Department of the Treasury.
- Aminex Therapeutics has filed 6 Form Ds with the SEC since 2014, most recently Dec 2025 ($15.1M sold to 162 investors).
- Status: Privately Held (backing).
Valued at $105.1M at its later-stage round, Dec 2025. Nothing has traded since.
- ·Watch Aminex Therapeutics: the Monday email on marks, rounds and moves
Aminex Therapeutics funding rounds
6 roundsWho backs Aminex Therapeutics
1Aminex Therapeutics valuation
Aminex Therapeutics was valued at $105 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Aminex Therapeutics raised?
Aminex Therapeutics has raised $47.6 million across 6 recorded rounds since 2014. The largest was an $8.3 million early-stage round in May 2018; the most recent was a $15.1 million early-stage round in Oct 2022.
Aminex Therapeutics has filed 6 Form Ds with the SEC since 2014, most recently in Dec 2025 ($15.1 million sold to 162 investors).
Aminex Therapeutics investors
1 investor is on record for Aminex Therapeutics, including United States Department of the Treasury. The early-stage round in Oct 2022 drew 162 investors.
About Aminex Therapeutics
Operator of a drug development company intended to focus on advancing novel immunotherapy for cancer treatment and cure. The company's immuno-oncology approach significantly reduces the uptake and production of polyamines and, in turn, myeloid-derived suppressor cells in the tumor microenvironment, allowing for activation of the innate immune system to attack solid tumors, enabling patients' innate immune systems to attack solid tumors in their bodies.
- Sector
- Healthcare
- HQ
- Kenmore, WA, United States
- Founded
- 2009
- Employees
- 7
- Website
- aminextx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.